CombinatoRx Becomes Zalicus

Xconomy Boston — 

Cambridge, MA-based drug developer CombinatoRx announced today that it has changed its name to Zalicus to better reflect its assets and focus, following its merger last year with Vancouver-based Neuromed Pharmaceuticals. The company garnered its first drug approval earlier this year for the pain treatment hydromorphone HCL (Exalgo), which is being marketed by healthcare products company Covidien (NYSE: COV). “Our new name reflects the Company’s transformation into a biopharmaceutical company with product revenues, two powerful and differentiated drug discovery platforms, a pipeline of product candidates and proven drug development expertise focused on the treatment of pain and inflammation,” announced Mark Corrigan, president and CEO of Zalicus (NASDAQ: ZLCS), which started trading under its new stock symbol today.